bioRxiv (Cold Spring Harbor Laboratory)
July 6, 2024
Chloe L. West, Georgia Bastos, Annabel Duran et al.
2 citations
preprint
Abstract Serotonergic psychedelics (e.g., psilocybin) have shown potential for treating psychiatric disorders, with therapeutic effects lasting weeks after a single dose. Predictive processing theories posit that psychedelics work by loosening priors or high-level beliefs, including ingrained biases that have become pathological, leading to shifts in bottom-up vs top-down information processing...
Psychoactives
July 3, 2024
Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al.
4 citations
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....
Endocrinology
July 1, 2024
Sheida Shadani, Kyna Conn, Zane B. Andrews et al.
49 citations
The resurgence of interest in psychedelics as treatments for psychiatric disorders necessitates a better understanding of potential sex differences in response to these substances. Sex as a biological variable (SABV) has been historically neglected in medical research, posing limits to our understanding of treatment efficacy. Human studies have provided insights into the efficacy of...
FOCUS: The Journal of Lifelong Learning in Psychiatry
July 1, 2024
Sasha Gorrell, Amanda E. Downey
3 citations
Unlike psychopharmacologic interventions for other psychiatric conditions, few medications have emerged as helpful in improving eating disorder cognitions and evidence-based psychotherapies fail many patients. Novel treatments are urgently needed to address anorexia nervosa (AN), which is increasingly prevalent and difficult to treat. This article provides an overview of preliminary...
FOCUS: The Journal of Lifelong Learning in Psychiatry
July 1, 2024
Claire J. Foldi, Paul Liknaitzky, Martin L Williams et al.
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the...
Journal of Pakistan Psychiatric Society
June 30, 2024
Nauman Ashraf
1 citation
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religious ceremonies to facilitate spiritual experiences. Lysergic acid diethylamide (LSD) was used clinically from the 1950s until its ban in 1967. Recently, there has been a resurgence of interest in psychedelics for treating mental health disorders such...
Biotechnology Progress
June 18, 2024
Xin Wang, Fiona C. Kanis, Caroline N. Broude et al.
2 citations
Abstract N ‐methylated tryptamines, such as the hallucinogenic natural products, psilocybin and N,N ‐dimethyltryptamine (DMT), are gaining interest from the medical community due to their potential as next generation treatments for mental health disorders. The clinical relevance of these compounds has driven scientists to develop biosynthetic production routes to a number of tryptamine drug...
Current Medical Research and Opinion
June 17, 2024
Francisco J Appiani, Stanley N. Caroff
5 citations
There is an increasing demand for effective treatments for depression, particularly for individuals grappling with treatment-resistant depression. Over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. However, preliminary findings from phase 2 studies have been inconclusive, prompting critical examination...
PeerJ
June 3, 2024
Mengyang Xu, Haifei Shi, Andor J. Kiss et al.
5 citations
Background Psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. Research on the mechanisms of these effects has historically focused on the direct effects of these drugs on neural processes. However, in addition to such neural effects, alterations in peripheral physiology may also contribute to their therapeutic effects. In...
Frontiers in Pharmacology
June 3, 2024
Gio Kim, Catherine K. Wang, Lily R. Aleksandrova et al.
3 citations
One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just...